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Introduction
The advent of biologic medications has considerably
increased the potential for treatment benefit in juvenile
idiopathic arthritis (JIA), with clinical remission being now
achievable in a substantial proportion of patients.
Objectives
To evaluate the outcome of etanercept (ETN) therapy in
Italian children with JIA.
Methods
This is a multicenter, observational study that includes all
children with JIA who were given ETN at Italian pediatric
rheumatology centers after January 2000. Patients were
classified in 2 groups: 1) children who were no longer tak-
ing ETN at study start; 2) patients who were still receiving
ETN at study start. Patients in Group 1 underwent only
retrospective assessments, whereas patients in Group 2
underwent both retrospective and cross-sectional assess-
ments. The primary outcome of the study were reasons for
ETN discontinuation in patients in Group 1, and achieve-
ment of the states of inactive disease (ID), minimal disease
activity (MDA) and parent- and child-acceptable symptom
state (PASS, CASS) in patients in Group 2. The above
states were assessed through both formal definitions and
JADAS cutoffs. The secondary outcome was the evaluation
of frequency and characteristics of ETN-related side effects.
Results
Twenty-five centers were asked to make a census of all
patients followed at the center who met the inclusion
criteria for Group 1 or Group 2. A total of 1230 patients
were included in the census. Of these patients, 624 were
still receiving ETN (Group 2), whereas 606 had discontin-
ued ETN (Group 1). So far, the data of 313 patients (145
in Group 1 and 168 in Group 2) have been collected.
Among the 145 patients in Group 1, reasons for ETN dis-
continuation included disease remission (41.4%), lack of
efficacy (31%), and side effects (25.3%). The results of
assessment of disease state through formal definitions in
106 children of the 168 children in Group 2 who had
already undergone the cross-sectional evaluation were the
following: ID 44.3%, MDA 76.4%, PASS 75.2%, CASS
68.9%. The percentages of patients who reached the same
disease states assessed through JADAS cutoffs were: ID
41.5%, MDA 50.9%, PASS 61.3%, CASS 56.6%. Serious
adverse events were seen in 8 of the 313 patients and
included inflammatory bowel disease (3 pts), tuberculosis
(1 pt), CMV hepatitis (1 pt), varicella complicated by
bronchopneumonia (1 pt), bladder carcinoma (1 pt);
1 patient died of streptococcal sepsis.
Conclusion
A substantial proportion of children currently receiving
ETN were in the states of ID or MDA, or were satisfied
with treatment outcome. The percentage of patients with
ID in the cross-sectional cohort was comparable to the
percentage of patients who were discontinued from ETN
for disease remission in the retrospective cohort. Serious
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